Table 3.
Survival outcomes according to risk scores at the first and second rounds of TACE
| Risk scores | Median survival (95% CI) | Survival rate | Cox regression | |||
|---|---|---|---|---|---|---|
| 1-year | 3-years | 5-years | HR (95% CI) | P value* | ||
| At the first TACE (n = 619) | ||||||
| mHAP-II | ||||||
| A-B (n = 283) | 43.7 (36.8–50.6) | 89.8% | 59.7% | 40.1% | 1 | |
| C-D (n = 336) | 21.5 (18.5–24.5) | 65.7% | 31.3% | 16.8% | 2.07 (1.71–2.50) | <0.001 |
| mHAP | ||||||
| A-B (n = 519) | 35.2 (31.6–38.8) | 83.6% | 49.7% | 30.8% | 1 | |
| C-D (n = 100) | 10.2 (8.3–12.1) | 40.2% | 15.5% | 9.3% | 2.73 (2.17–3.45) | <0.001 |
| HAP | ||||||
| A-B (n = 394) | 39.8 (35.3–44.3) | 86.1% | 53.9% | 34.1% | 1 | |
| C-D (n = 225) | 18.6 (14.2–23.0) | 60.2% | 27.4% | 15.7% | 2.01 (1.66–2.42) | <0.001 |
| At the second TACE (n = 514) | ||||||
| mHAP-II | ||||||
| A-B (n = 263) | 38.6 (33.8–43.4) | 86.5% | 51.9% | 33.3% | 1 | |
| C-D (n = 251) | 17.2 (14.9–19.5) | 60.3% | 24.2% | 11.2% | 2.28 (1.86–2.80) | <0.001 |
| mHAP | ||||||
| A-B (n = 441) | 30.0 (26.6–33.4) | 78.9% | 42.6% | 25.0% | 1 | |
| C-D (n = 73) | 8.5 (6.8–10.2) | 39.4% | 12.7% | 7.0% | 2.64 (2.02–3.44) | <0.001 |
| HAP | ||||||
| A-B (n = 337) | 32.6 (27.8–37.4) | 81.6% | 46.5% | 27.8% | 1 | |
| C-D (n = 177) | 17.2 (14.0–20.4) | 57.5% | 22.8% | 12.3% | 1.97 (1.60–2.41) | <0.001 |
P value* indicates a comparison with A-B class of risk scores
HAP hepatoma arterial-embolization prognostic, mHAP modified HAP, CI confidence interval, TACE trans-arterial chemoembolization